NCT06875128View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

August 31, 2029

Conditions
Metastatic Breast Cancer in the Liver
Interventions
DRUG

Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)

Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)

DRUG

Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)

Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)

All Listed Sponsors
lead

Delcath Systems Inc.

INDUSTRY